TokenPost·
Xenon Plans Q1 2027 Azetukalner Study With $1.2 Billion in Cash and Securities
Xenon submitted a new drug application for focal seizures in Q3 2026; topline results from X-NOVA2 are expected in December.
More news
- TokenPostKalshi Entertainment Markets Reach $813 Million in Volume Through Sept. 25
- TokenPostPublic First Action Says AI Safety Advocates Saw Midterms as a Major Win
- Bitcoin.com NewsPrediction Markets Never Bought Trump’s Dana White Press Secretary Pick
- CryptoSlateAI agents break safety rules by remembering harmless user context
- TokenPostSouth Korean Police Begin Moving Seized Crypto to Upbit Custody
- TokenPostOgilvy and CAA Develop Echo Platform for Consent-Based Celebrity Ads